Treatment of insulin resistance in diabetes mellitus

European Journal of Pharmacology

Volumn 490, Issue 1-3, 2004, Pages 135-146

  Lebovitz, Harold E ^a   Banerji, Mary Ann ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Diabetes mellitus; Insulin; Obesity

Indexed keywords

ANTIINFLAMMATORY AGENT; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL; TROGLITAZONE;

CARDIOVASCULAR RISK; DRUG SURVEILLANCE PROGRAM; DYSLIPIDEMIA; FAT BODY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; KETOGENESIS; LIFESTYLE; LIPID COMPOSITION; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 1842633862     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.02.051     Document Type: Article

References (98)

1. Albu J.B., Murphy L., Frager D.H., Johnson J.A., Pi-Sunyer F.X. Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women. Diabetes. 46:1997;456-462.
2. Basu-Modak S., Braissant O., Escher P., Desvergne B., Honegger P., Wahli W. Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures. J. Biol. Chem. 274:1999;35881-35888.
3. Buchanan T.A., Xiang A.H., Peters R.K., Kjos S.L., Marroquin A., Goico J., Ochoa C., Tan S., Berkowitz K., Hodis H.N., Azen S.P. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 51:2002;2796-2803.
4. Caballero A.E., Saouaf R., Lim S.C., Hamdy O., Abou-Elenin K., O'Connor C., Logerfo F.W., Horton E.S., Veves A. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism. 52:2003;173-180.
5. Calnek D.S., Mazzella L., Roser S., Roman J., Hart C.M. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler. Thromb. Vasc. Biol. 23:2003;52-57.
6. Charles M.A., Morange P., Eschwege E., Andre P., Vague P., Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care. 21:1998;1967-1972.
7. Chu N.V., Kong A.P., Kim D.D., Armstrong D., Baxi S., Deutsch R., Caulfield M., Mudaliar S.R., Reitz R., Henry R.R., Reaven P.D. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 25:2002;542-549.
8. Cristiano L., Bernardo A., Ceru M.P. Peroxisome proliferator-activated receptors (PPARs) and peroxisomes in rat cortical and cerebellar astrocytes. J. Neurocytol. 30:2001;671-683.
9. DeFronzo R.A., Goodman A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333:1995;541-549.
10. Dello-Russo C., Gavrilyuk V., Weinberg G., Almeida A., Bolanos J.P., Palmer J., Pelligrino D., Galea E., Feinstein D.L. Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J. Biol. Chem. 278:2003;5828-5836.
11. Deplanque D., Gele P., Petrault O., Six I., Furman C., Bouly M., Nion S., Dupuis B., Leys D., Fruchard J.C., Cecchelli R., Staels B., Duriez P., Bordet R. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J. Neurosci. 23:2003;6264-6271.
12. Dib K., Whitehead J.P., Humphreys P.J., Soos M.A., Baynes K.C.R., Kumar S., Harvey T., O'Rahilly S. Impaired activation of phosphoinositide 3-kinase by insulin in fibroblasts from patients with severe insulin resistance and pseudoacromegaly. A disorder characterized by selective postreceptor insulin resistance. J. Clin. Invest. 101:1998;1111-1120.
13. Dresner A., Laurent D., Marcucci M., Griffin M.E., Dufour S., Cline G.W., Slezak L.A., Andersen D.K., Hundal R.S., Rothman D.L., Petersen K.F., Shulman G.I. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. 103:1999;253-259.
14. Einhorn D., Rendell M., Rosenzweig J., Egan J.W., Mathisen A.L., Schneider R.L. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin. Ther. 22:2000;1395-1409.
15. Emoto M., Anno T., Sato Y., Tanabe K., Okuya S., Tanizawa Y., Matsutani A., Oka Y. Rosiglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes. 50:2001;1166-1170.
16. Festa A., Hanley A.J., Tracy R.P., D'Agostino R. Jr., Haffner S.M. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation. 108:2003;1822-1830.
17. Flier J.S., Mantzoros C. Syndromes of insulin resistance and mutant insulin. DeGroot L.J., Jameson J.L. Endocrinology. fourth edition:2001;799-809 WB Saunders, Philadelphia.
18. Fonseca V., Rosenstock J., Patwardhan R., Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. A randomized controlled trial. JAMA. 283:2000;1695-1702.
19. Freed M.I., Ratner R., Marcovina S.M., Kreider M.M., Biswas N., Cohen B.R., Brunzell J.D. Effect of rosiglitazone alone and in combination with atorvistatin on the metabolic abnormalities in type 2 diabetes mellitus. Am. J. Cardiol. 90:2002;947-952.
20. Fullert S., Schneider F., Haak E., Rau H., Badenhoop K., Lubben G., Usadel K.H., Konrad T. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 87:2002;5503-5506.
21. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348:2003;383-393.
22. Gin H., Roudaut M.F., Vergnot V., Baillet L., Rigalleau V. Effect of metformin on fibrinolytic parameters in insulin-treated, type 2 diabetic patients. Diabetes Metab. 29:2003;505-508.
23. Goodpaster B.H., Kelley D.E., Wing R.R., Meier A., Thaete F.L. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes. 48:1999;839-847.
24. Gurnell M., Savage D.B., Chatterjee V.K., O'Rahilly S. The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J. Clin. Endocrinol. Metab. 88:2003;2412-2421.
25. Hadigan C., Meigs J.B., Rabe J., D'Agostino R.B., Wilson P.W., Lipinska I., Tofler G.H., Grinspoon S.S. Framingham Heart Study. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J. Clin. Endocrinol. Metab. 86:2001;939-943.
26. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 106:2002;679-684.
27. Hallsten K., Vitanen K.A., Lonnqvist F., Sipila H., Oksanen A., Viljanen T., Ronnemaa T., Viikari J., Knuuti J., Nuutila P. Rosiglitazone but not metformin enhances insulin-and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes. 51:2002;3479-3485.
28. Hanley A.J., Williams K., Stern M.P., Haffner S.M. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care. 25:2002;1177-1184.
29. Harte A.L., McTernan P.G., McTernan C.L., Smith S.A., Barnett A.H., Kumar S. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. Diabetes Obes. Metab. 5:2003;302-310.
30. Hattori Y., Matsumura M., Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc. Res. 58:2003;186-195.
31. Hsueh W.A., Jackson S., Law R.E. Control of vascular cell proliferation and migration by PPARγ Diabetes Care. 24:2001;392-397.
32. Hundal R.S., Petersen K.F., Mayerson A.B., Randhawa P.S., Inzucchi S., Shoelson S.E., Shulman G.I. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest. 109:2002;1321-1326.
33. Inuoe H., Jiang X.F., Katayama T., Osada S., Umesono K., Namura S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferators-activated alpha in mice. Neurosci. Lett. 352:2003;203-206.
34. Inzucchi S.E., Maggs D.G., Spollett G.R., Page S.L., Rife F.S., Walton V., Shulman G.I. Efficacy and metabolic effects of metformin and troglitazone in type 2 diabetes mellitus. N. Engl. J. Med. 338:1998;867-872.
35. Isomaa B., Almgren P., Tuomi T., Forsén B., Lahti K., Nissén M., Taskinen M.-R., Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 24:2001;683-689.
36. Janand-Delenne B., Chagnaud C., Raccah D., Alessi M.C., Juhan-Vague I., Vague P. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int. J. Obes. Relat. Metab. Disord. 22:1998;312-317.
37. Kahn S.E., Prigeon R.L., McCulloch D.K., Boyko E.J., Bergman R.N., Schwartz M.W., Neifing J.L., Ward W.K., Beard J.C., Palmer J.P. Quantification of the relationship between insulin sensitivity and B-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 42:1993;1663-1672.
38. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., Nathan D.M. Diabetes Prevention Program Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346:2002;393-403.
39. Kockx M., Leenen R., Seidell J., Princen H.M., Kooistra T. Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss. Thromb. Haemost. 82:1999;1490-1496.
40. Kohler H.P., Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med. 342:2000;1792-1801.
41. Kruszynska Y.T., Yu J.G., Olefsky J.M., Sobel B.E. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes. 49:2000;633-639.
42. Law R.E., Goetze S., Xi X.-P., Jackson S., Kawano Y., Demer L., Fishbein M.C., Meehan W.P., Hsueh W.A. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation. 101:2000;1311-1318.
43. Lebovitz H.E. Insulin secretogogues: old and new. Diabetes Rev. 7:1999;139-153.
44. Lebovitz H.E. Insulin resistance: definition and consequences. Exp. Clin. Endocrinol. Diabetes. 109(Suppl. 2):2001;S135-S148.
45. Lebovitz H.E. Oral therapies for diabetic hyperglycemia. Endocrinol. Metab. Clin. N. Am. 30:2001;909-933.
46. Lebovitz H.E. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus. Am. J. Cardiol. 90:2002;34G-41G. (suppl).
47. Lebovitz H.E. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab. Res. Rev. 18:2002;S23-S29.
48. Lebovitz H.E. The relationship of obesity to the metabolic syndrome. Int. J. Clin. Pract. Suppl. 134:2003;18-27.
49. Lebovitz H.E., Banerji M.A. Insulin resistance and its treatment by thiazolidinediones. Recent Prog. Horm. Res. 56:2001;265-294.
50. Lebovitz H.E., Dole J.F., Patwardhan R., Rappaport E.B., Freed M.I. Rosiglitazone monotherapy is effective in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 86:2001;280-288.
51. Lebovitz H.E., Kreider M., Freed M.I. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 25:2002;815-823.
52. O2max. J. Appl. Physiol. 90:2001;99-104.
53. Mather K.J., Verma S., Anderson T.J. Improved endothelial function with metformin in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 37:2001;1344-1350.
54. Mavri A., Stegnar M., Krebs M., Sentocnik J.T., Geiger M., Binder B.R. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler. Thromb. Vasc. Biol. 19:1999;1582-1587.
55. Mavri A., Alessi M.C., Bastelica D., Geel-Georgelin O., Fina F., Sentocnik J.T., Stegnar M., Juhan-Vague I. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia. 44:2001;2025-2031.
56. Mayerson A.B., Hundal R.S., Dufour S., Lebon V., Befroy D., Cline G.W., Enocksson S., Inzucchi S.E., Shulman G.I., Petersen K.F. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 51:2002;797-802.
57. Miyazaki Y., Mahankali A., Matsuda M., Glass L., Mahankali S., Ferrannini E., Cusi K., Mandarino L.J., DeFronzo R.A. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 24:2001;710-719.
58. Moreno S., Farioli-Vecchioli S., Ceru M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience. 123:2004;131-145.
59. Mudaliar S., Chang A.R., Henry R.R. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology and clinical implications. Endocr. Pract. 9:2003;406-416.
60. Murata T., Hata Y., Ishibashi T., Kim S., Hsueh W.A., Law R.E., Hinton D.R. Response of experimental retinal neovascularization to thiazolidinediones. Arch. Ophthalmol. 119:2001;709-717.
61. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., Winter M.L., Porte D., Semenkovich C.F., Smith S., Young L.H., Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Circulation. 108:2003;2941-2948.
62. Paradisi G., Steinberg H.O., Shepard M.K., Hook G., Baron A.D. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88:2003;576-580.
63. Pare A., Dumont M., Lemieux I., Brochu M., Almeras N., Lemieux S., Prud'homme D., Despres J.-P. Is the relationship between adipose tissue and waist girth altered by weight loss in obese men? Obes. Res. 9:2001;526-534.
64. Parulkar A.A., Pendergrass M.L., Granda-Ayala R., Lee R., Fonseca V.A. Nonhypoglycemic effects of thiazolidinediones. Ann. Intern. Med. 134:2001;61-71.
65. Pasceri V., Wu H.D., Willerson J.T., Yeh E.T.H. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation. 101:2000;235-238.
66. Pavo I., Jermendy G., Varkonyi T.T., Kerenyi Z., Gyimesi A., Shoustov S., Shestakova M., Herz M., Johns D., Schluchter B.J., Festa A., Tan M.H. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 88:2003;1637-1645.
67. Pontiroli A.E., Pizzocri P., Librenti M.C., Vedani P., Marchi M., Cucchi E., Orena C., Paganelli M., Giacomelli M., Ferla G., Folli F. Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three year study. J. Clin. Endocrinol. Metab. 87:2002;3555-3561.
68. Raji A., Seely E.W., Bekins S.A., Williams G.H., Simonson D.C. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 26:2003;172-178.
69. Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14,719 initially healthy American women. Circulation. 107:2003;391-397.
70. Robins S.J., Rubins H.B., Faas F.H., Schaffer E.J., Elam M.B., Anderson J.W., Collins D. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL intervention trial (VA-HIT). Diabetes Care. 26:2003;1513-1517.
71. Roth A.D., Leisewitz A.V., Jung J.E., Cassina P., Barbeito L., Inestrosa N.C., Bronfman M. PPAP gamma activators induce growth arrest and process extension in B12 oligodendrocyte-like cells and terminal differentiation of cultured oligodendrocytes. J. Neurosci. Res. 72:2003;425-435.
72. Rubins H.B., Robins S.J., Collins D., Nelson D.B., Elam M.B., Schaefer E.J., Faas F.H., Anderson J.W. Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the department of veterans affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch. Intern. Med. 162:2002;2597-2604.
73. Saluja I., Granneman J.G., Skoff R.P. PPAR delta agonists stimulate oligodendrocyte differentiation in cell culture. Glia. 33:2001;191-204.
74. Satoh N., Ogawa Y., Usui T., Tagami T., Kono S., Uesugi H., Sugiyama H., Sugawara A., Yamada K., Shimatsu A., Kuzuya H., Nakao K. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 26:2003;2493-2499.
75. Sidhu J.S., Cowan D., Kaski J.C. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J. Am. Coll. Cardiol. 42:2003;1757-1763.
76. Shadid S., Jensen M.D. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care. 26:2003;3148-3152.
77. Smith S.R., Zachweija J.J. Visceral adipose tissue: a critical review of intervention strategies. Int. J. Obes. Relat. Metab. Disord. 23:1999;329-335.
78. Stern M. The insulin resistance syndrome. Alberti K.G.M.M., Zimmet P., DeFronzo R.A., Keen H. International Textbook of Diabetes Mellitus. Second edition:1997;255-283 Wiley, Chichester.
79. Tak P.P., Firestone G.S. NFκB: a key role in inflammatory diseases. J. Clin. Invest. 107:2001;7-11.
80. Takagi T., Yamamuro A., Tamita K., Yamabe K., Katayama M., Mizoguchi S., Ibuki M., Tani T., Tanabe K., Nagai K., Shiratori K., Morioka S., Yoshikawa J. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am. Heart J. 146:2003;E5.
81. Tang W.H.W., Francis G.S., Hoogwerf B.J., Young J.B. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J. Am. Coll. Cardiol. 41:2003;1394-1398.
82. Tchernof A., Nolan A., Sites C.K., Ades P.A., Poehlman E.T. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 105:2002;564-569.
83. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., Keinanen-Kiukaanniemi S., Laakso M., Louheranta A., Rastas M., Salminen V., Uusitupa M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346:2002;393-403.
84. UK Prospective Diabetes Study Group Overview of 6 years therapy of type 2 diabetes: a progressive disease (UKPDS 16). Diabetes. 44:1995;1249-1258.
85. UK Prospective Diabetes Study Group Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 352:1998;854-865.
86. Virkamaki A., Ueki K., Kahn C.R. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J. Clin. Invest. 103:1999;931-943.
87. Virtanen K.A., Hallsten K., Parkkola R., Janatuinen T., Lonnqvist F., Viljanen T., Ronnemaa T., Knuuti J., Huupponen R., Lonnroth P., Nuutila P. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes. 52:2003;283-290.
88. Weinsier R.L., Hunter G.R., Gower B.A., Schutz Y., Darnell B.E., Zuckerman P.A. Body fat distribution in white and black women: different patterns of intraabdominal and subcutaneous abdominal adipose tissue utilization after weight loss. Am. J. Clin. Nutr. 74:2001;631-636.
89. Weyer C., Bogardus C., Mott D.M., Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin. Invest. 104:1999;787-794.
90. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43:2000;527-550.
91. Willson T.M., Lambert M.H., Kliewer S.A. Peroxisome proliferator- activated receptor γ and metabolic disease. Ann. Rev. Biochem. 70:2001;341-367.
92. Winkler K., Konrad T., Fullert S., Friedrich I., Destani R., Baumstark M.W., Krebs K., Wieland H., Marz W. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care. 26:2003;2588-2594.
93. Woods J.W., Tanen M., Figueroa D.J., Biswas C., Zycband E., Moller D.E., Austin C.P., Berger J.P. Localization of PPAR delta in murine central nervous system: expression in oligodendrocytes and neurons. Brain Res. 975:2003;10-21.
94. Yang W.-S., Matsuzawa Y., Jeng C.-Y., Wang J.-P., Wu T.-J., Chen C.-L., Tanaka S., Tai T.-Y., Funahashi T., Chuang L.-M. Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 25:2002;376-380.
95. Yatagai T., Nakamura T., Nagasaka S., Kusaka I., Ishikawa S., Yoshitaka A., Ishibashi S. Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects. Diabetes Res. Clin. Pract. 63:2004;19-26.
96. Yu J.G., Kruszynska Y.T., Mulford M.I., Olefsky J.M. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes. 48:1999;2414-2421.
97. Yu J.G., Javorschi S., Hevener A.L., Kruszynska Y.T., Norman R.A., Sinha M., Olefsky J.M. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese and type 2 diabetic subjects. Diabetes. 51:2002;2968-2974.
98. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z.-W., Karin M., Shoelson E. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ Science. 293:2001;1673-1677.